Single-Cell Insights: Myeloid S100A8/A9 as a Regulator of Cardiac Hypertrophy Progression

Study Background and Research Question

Heart failure (HF) remains a leading cause of morbidity and mortality worldwide, with chronic cardiac hypertrophic remodeling recognized as a central risk factor in its development. In the context of pressure overload—such as that induced by hypertension or valvular disease—the heart initially undergoes adaptive hypertrophy to preserve function. However, persistent overload can drive a maladaptive transition toward heart failure, characterized by inflammation, fibrosis, and contractile dysfunction. While immune cell infiltration is established as a pivotal event in this transition, the precise myeloid regulators orchestrating these processes have not been fully characterized (paper).

Key Innovation from the Reference Study

Wei-Jia Yu and colleagues employ single-cell RNA sequencing (scRNA-seq) to systematically dissect the immune landscape of the heart during pressure overload. Their work identifies the myeloid S100A8/A9 heterodimer as a novel and central regulator of the transition from adaptive hypertrophy to heart failure. This is significant because S100A8/A9, previously recognized as a biomarker in inflammatory and fibrotic diseases, is now mechanistically linked to maladaptive cardiac remodeling (paper).

Methods and Experimental Design Insights

The study utilizes a multi-modal approach integrating in vivo, in vitro, and computational analyses:

• Model Induction: Heart failure and cardiac hypertrophy were induced in mice using transverse aortic constriction (TAC), mimicking pressure overload over 1–4 weeks.
• Single-Cell RNA-seq: Published scRNA-seq datasets were re-analyzed to explore the heterogeneity of CD45+ immune cells and map the cellular sources of S100A8/A9 across the pressure overload timeline.
• Genetic Models: S100A9 knockout (KO) mice, as well as bone marrow–chimeric mice (wild-type recipients of S100A9-KO bone marrow), were employed to dissect the functional role of myeloid-derived S100A8/A9.
• Pharmacological Inhibition: The S100A9 inhibitor ABR-238901 was administered to wild-type mice to assess the therapeutic potential of S100A8/A9 targeting.
• In Vitro Coculture: Cardiac cell coculture systems allowed direct interrogation of S100A8/A9’s paracrine effects on hypertrophic signaling.

This combination of genetic, pharmacological, and single-cell approaches provides robust evidence for cell-type-specific contributions to disease progression.

Protocol Parameters

• assay | transverse aortic constriction (TAC) | 1–4 weeks | Induces pressure overload and models adaptive-to-maladaptive cardiac transition | paper
• assay | single-cell RNA sequencing | ~10,000 cells/sample | Dissects immune cell heterogeneity and gene expression at single-cell resolution | paper
• assay | S100A9 knockout mouse | genetic deletion | Tests functional requirement of S100A8/A9 in myeloid cells | paper
• assay | S100A9 pharmacological inhibitor (ABR-238901) | 30 mg/kg/day | Acute inhibition of S100A8/A9 axis in vivo | paper
• assay | Western blot phosphatase inhibitor inclusion | as per manufacturer’s protocol | Preserves phosphorylation signals for accurate downstream analysis of signaling pathways | workflow_recommendation

Core Findings and Why They Matter

The research reveals several pivotal findings:

• Elevation of S100A8/A9: S100A8/A9 levels are significantly upregulated in both HF patients and TAC-induced mouse models during the transition to heart failure (paper).
• Myeloid Source and Mechanism: Neutrophils emerge as early sources of S100A8/A9, initiating an inflammatory cascade via the p38 MAPK/JNK/AP-1 pathway, stimulating IL-1β and chemokine (CCL2, CCL6) production. This, in turn, recruits CCR2+ macrophages, which further amplify inflammation and fibrosis through NF-κB/NLRP3, AKT/Calcineurin A, and TGF-β/Smad2 signaling axes.
• Functional Validation: Disruption of S100A8/A9 in myeloid cells (via S100A9-KO or bone marrow chimera) markedly attenuates the maladaptive hypertrophy and progression to HF, confirming its central regulatory role.
• Therapeutic Implications: Pharmacological inhibition of S100A8/A9 with ABR-238901 protects against TAC-induced cardiac dysfunction, supporting the axis as a promising therapeutic target.

These discoveries elucidate a stepwise, immune-driven mechanism for maladaptive remodeling and offer concrete molecular targets for intervention.

Comparison with Existing Internal Articles

Recent internal articles, such as Preserving the Phosphoproteome: Strategic Use of Phosphatase Inhibitor Cocktail 1 and Phosphatase Inhibitor Cocktail 1: Unlocking Precision, emphasize the critical importance of preserving protein phosphorylation during sample collection and processing for accurate analysis of signaling pathways. The present study’s focus on phospohorylation-driven mechanisms (e.g., p38 MAPK, JNK, AKT/Calcineurin) aligns with these recommendations by highlighting the necessity of robust phosphatase inhibition to avoid artifactual loss of phosphorylation signals during Western blotting and phosphoproteomic analysis (paper, workflow_recommendation). The use of defined alkaline phosphatase inhibitors, such as those described in the reviewed internal articles, directly supports the reproducibility and interpretability of such studies.

Limitations and Transferability

While the integration of single-cell, genetic, and pharmacological approaches provides strong internal validity, several limitations merit consideration:

• Although murine TAC models recapitulate key aspects of human pressure-overload cardiomyopathy, species-specific differences in immune responses and cardiac remodeling may affect translation to human pathology (paper).
• The S100A8/A9 axis was primarily studied in the context of pressure overload; its role in other forms of cardiac stress (e.g., ischemia, metabolic dysfunction) remains to be established.
• Therapeutic inhibition was tested with a single small molecule (ABR-238901), and long-term safety or off-target effects were not fully evaluated.

Nevertheless, the mechanistic insights into immune-driven maladaptive hypertrophy provide a strong foundation for further translational research.

Research Support Resources

To ensure reliable detection of phosphorylation-dependent signaling events—such as those implicated in the S100A8/A9-mediated progression to heart failure—researchers are encouraged to incorporate robust phosphatase inhibition strategies during sample processing. Products like Phosphatase Inhibitor Cocktail 1 (100X in DMSO) (SKU K1012) from APExBIO are formulated to inhibit alkaline and serine/threonine phosphatases, thereby preserving protein phosphorylation states for downstream applications including Western blotting, co-immunoprecipitation, and phosphoproteomic analysis (workflow_recommendation). This aligns with best practices highlighted in both recent literature and expert workflow recommendations for high-fidelity signaling studies.